Key result
Heparin and its derivatives effectively modulate multifactorial components of thromboembolic disorders, including hypercoagulable, proinflammatory, and proangiogenesis states.
Heparin's success in treating multifactorial thromboembolic diseases is attributed to its polypharmacological mechanisms of action across thrombosis, angiogenesis, and inflammation.
Answers are grounded in this paper and cite their sources.
Supports heparin's polypharmacology in complex thrombosis; leaves open prospective trials isolating non-anticoagulant benefits.
The key reason behind the success of heparin in thrombosis and beyond is its polypharmacological sites of action for the prevention and treatment of multifactorial diseases that will only benefit slightly with single pharmacological mechanism-based agents. Thromboembolic disorders are driven by hypercoagulable, hyperactive platelet, proinflammatory, endothelial dysfunction, and proangiogenesis states. Heparin can effectively modulate all of those multifactorial components, as well as the interface among those components.
No takes yet. Share an insight, caveat, or question.
Shaker A. Mousa (2007) conducted a review in Thromboembolic disorders. Heparin, Low Molecular Weight Heparin, and Derivatives was evaluated. Heparin and its derivatives effectively modulate multifactorial components of thromboembolic disorders, including hypercoagulable, proinflammatory, and proangiogenesis states.
Synapse has enriched 10 related papers. Consider them for comparative context: